Clinical trial
A Double Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MK-7240/PRA023 in Subjects With Systemic Sclerosis Associated With Interstitial Lung Disease (SSc-ILD)
NCT05270668 is registered in ClinicalTrials.gov with Prometheus Biosciences, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Double Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MK-7240/PRA023 in Subjects With Systemic Sclerosis Associated With Interstitial Lung Disease (SSc-ILD)
- Lead sponsor
- Prometheus Biosciences, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
- Phase
- Phase 2
- Overall status
- Active, not recruiting
- Start date
- March 29, 2022
- Completion date
- November 16, 2026
- Enrollment
- 154 (actual)
- Sites
- 95
Conditions
As the registry lists them; a condition with its own page is linked.
diffuse cutaneous systemic sclerosis, interstitial lung disease